Please assess the completion status of the following clinical trial:

Trial Title: The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~-Without fever for 72 hours prior to vaccination~Exclusion Criteria:~* Prior receipt of any pneumococcal polysaccharide vaccine or any pneumococcal conjugate vaccine~* Known or suspected to be immunocompromised~* Functional or anatomic asplenia~* History of autoimmune disease~* Evidence of dementia or cognitive impairment~* Use of any immunosuppressive therapy~* Received a licensed non-live vaccine administered within the 14 days prior to receipt of study vaccine or scheduled to receive any other licensed vaccine within 30 days following receipt of study vaccine~* Received a licensed live virus vaccine within 30 days prior of receipt of study vaccine or is scheduled to receive any other licensed vaccine within 30 days of receipt of study vaccine~* Received any vaccine containing diphtheria toxoid within 6 months prior to receipt of study vaccine~* Received a blood transfusion or blood products within the 6 months before receipt of study vaccine or scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine~* History of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease~* Received antibiotic therapy for any acute illness within 72 hours before receipt of study vaccine

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
- PNEUMOVAX® 23 (Type: ACTIVE_COMPARATOR): Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.
- PREVNAR 13® (Type: ACTIVE_COMPARATOR): Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).